Evidence map›Paper›PMID 35227699›Full record

ArticleAmerican journal of ophthalmology2022

The Blue Light Hazard Versus Blue Light Hype.

Martin A Mainster, Oliver Findl, H Burkhard Dick, Thomas Desmettre, Gerardo Ledesma-Gil, Christine A Curcio, Patricia L Turner

Open access · greenAbstract read
In one paragraph

Article in American journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. The effect of fingolimod (FTY720) protecting the retina of rats from light-induced retinal degeneration (LIRD).Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  3. Article
  4. Article
  5. Photooxidative molecular damage under blue light.Experimental & molecular medicine · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Martin A MainsterDepartment of Ophthalmology, University of Kansas School of Medicine, Prairie Village, Kansas, USA. Electronic address: mmainste@kumc.edu.
Oliver FindlVienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna, Austria.
H Burkhard DickDepartment of Ophthalmology, Ruhr University Eye Hospital, Science, Bochum, Germany.
Thomas DesmettreCentre de Retine Medicale, Marquette-Lez-Lille, France.
Gerardo Ledesma-GilRetina Department, Institute of Ophthalmology, Fundación Conde de Valenciana, Mexico City, Mexico.
Christine A CurcioDepartment of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Patricia L TurnerDepartment of Ophthalmology, University of Kansas School of Medicine, Prairie Village, Kansas, USA.
University of Kansas · USHanusch Hospital · ATInstitute of Ophthalmology · MXUniversity of Alabama at Birmingham · US

Funding

Visual Phenotyping CoreP30EY003039 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul Douglas Gamlin · 1985 to 2026
$16.9M
Functionally Validated Structural Endpoints for Early AMDR01EY029595 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CURCIO, CHRISTINE A, OWSLEY, CYNTHIA · 2019 to 2023
$4.1M
A hyperspectral approach to RPE fluorophores in AMDR01EY027948 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ACH, THOMAS, CURCIO, CHRISTINE A · 2017 to 2025
$3.8M
NEI NIH HHS P30 EY003039NEI NIH HHS R01 EY027948NEI NIH HHS R01 EY029595
6 · The paper itself

Abstract

purposeThe blue light hazard is the experimental finding that blue light is highly toxic to the retina (photic retinopathy), in brief abnormally intense exposures, including sungazing or vitreoretinal endoillumination. This term has been misused commercially to suggest, falsely, that ambient environmental light exposure causes phototoxicity to the retina, leading to age-related macular degeneration (AMD). We analyze clinical, epidemiologic, and biophysical data regarding blue-filtering optical chromophores.

designPerspective.

methodsAnalysis and integration of data regarding the blue light hazard and blue-blocking filters in ophthalmology and related disciplines.

resultsLarge epidemiologic studies show that blue-blocking intraocular lenses (IOLs) do not decrease AMD risk or progression. Blue-filtering lenses cannot reduce disability glare because image and glare illumination are decreased in the same proportion. Blue light essential for optimal rod and retinal ganglion photoreception is decreased by progressive age-related crystalline lens yellowing, pupillary miosis, and rod and retinal ganglion photoreceptor degeneration. Healthful daily environmental blue light exposure decreases in older adults, especially women. Blue light is important in dim environments where inadequate illumination increases risk of falls and associated morbidities.

conclusionsThe blue light hazard is misused as a marketing stratagem to alarm people into using spectacles and IOLs that restrict blue light. Blue light loss is permanent for pseudophakes with blue-blocking IOLs. Blue light hazard misrepresentation flourishes despite absence of proof that environmental light exposure or cataract surgery causes AMD or that IOL chromophores provide clinical protection. Blue-filtering chromophores suppress blue light critical for good mental and physical health and for optimal scotopic and mesopic vision.

Indexed as

Cataract ExtractionLens, CrystallineLenses, IntraocularMacular DegenerationAgedFemaleGlareHumansLight

Identifiers

PMID35227699
PMCPMC10243475
OpenAlexW4214666060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.